Key result
Aspirin (81 mg/day) and ticlopidine (100-200 mg/day) effectively inhibited platelet aggregation, with a maximum aggregation rate of ≤60% identified as an appropriate therapeutic target for evaluating antiplatelet efficacy.
Why the study?
Does aspirin or ticlopidine effectively inhibit platelet aggregation in patients with chronic cerebral thrombosis, and what are the optimal measurement conditions to evaluate their efficacy?
Observational (n=80)
Does aspirin or ticlopidine effectively inhibit platelet aggregation in patients with chronic cerebral thrombosis, and what are the optimal measurement conditions to evaluate their efficacy?
Platelet aggregation testing using 2 μg/ml collagen for aspirin and 2 μM ADP for ticlopidine is useful for monitoring antiplatelet therapy efficacy in cerebral thrombosis patients, with a target maximum aggregation rate of ≤60%.
May aid monitoring of antiplatelet therapy in cerebral thrombosis; leaves open whether ≤60% target improves outcomes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Komiya et al. (1993) conducted an observational in Cerebral thrombosis (n=80). Aspirin and Ticlopidine vs. Baseline (pre-administration) was evaluated on Platelet aggregation rate (maximum and 5-minute aggregation). Aspirin (81 mg/day) and ticlopidine (100-200 mg/day) effectively inhibited platelet aggregation, with a maximum aggregation rate of ≤60% identified as an appropriate therapeutic target for evaluating antiplatelet efficacy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: